Fast Quantitative Urinary Proteomic Profiling Workflow for Biomarker Discovery in Kidney Cancer

Overview

Journal Clin Proteomics

Publisher Biomed Central

Date 2019 Jan 5

PMID 30607141

Citations 9

Authors

Lin Lin

Quan Yu

Jiaxin Zheng

Zonglong Cai

Ruijun Tian

Affiliations

Soon will be listed here.

Abstract

Background: Urine has evolved as a promising body fluids in clinical proteomics because it can be easily and noninvasively obtained and can reflect physiological and pathological status of the human body. Many efforts have been made to characterize more urinary proteins in recent years, but few have focused on the analysis throughput and detection reproducibility. Increasing the urine proteomic profiling throughput and reproducibility is urgently needed for discovering potential biomarker in large cohorts.

Methods: In this study, we developed a fast and robust workflow for streamlined urinary proteome analysis. The workflow integrate highly efficient sample preparation technique and urinary specific data-independent acquisition (DIA) approach. The performance of the workflow was systematically evaluated and the workflow was subsequently applied in a proof-of-concept urine proteome study of 21 kidney cancer (KC) patients and 22 healthy controls.

Results: With this workflow, the entire sample preparation process takes less than 3 h and allows multiplexing on standard centrifuges. Without pre-fractionation, our newly developed DIA method allows quantitative analysis of ~ 1000 proteins within 80 min of MS time (~ 15 samples/day). The quantitation accuracy of the whole workflow was excellent with median CV of 9.1%. The preliminary study on KC identified 125 significantly changed proteins.

Conclusions: The result suggested the feasibility of applying the high throughput workflow in extensive urinary proteome profiling and clinical relevant biomarker discovery.

Citing Articles

Effect of dynamic exclusion and the use of FAIMS, DIA and MALDI-mass spectrometry imaging with ion mobility on amyloid protein identification.

Aguilan J, Lim J, Racine-Brzostek S, Fischer J, Silvescu C, Cornett S Clin Proteomics. 2024; 21(1):47.

PMID: 38961380 PMC: 11223398. DOI: 10.1186/s12014-024-09500-w.

Development and validation of machine learning models for diagnosis and prognosis of cancer by urinary proteomics, based on the FLEMENGHO cohort.

Wang S, Wei D, Zhao Y, Pang X, Zhang Z Am J Cancer Res. 2024; 14(2):643-654.

PMID: 38455408 PMC: 10915340.

Rapid structural discrimination of IgG antibodies by multicharge-state collision-induced unfolding.

Yin Z, Du M, Chen D, Zhang W, Huang W, Wu X RSC Adv. 2022; 11(58):36502-36510.

PMID: 35494361 PMC: 9043582. DOI: 10.1039/d1ra06486j.

HBFP: a new repository for human body fluid proteome.

Shao D, Huang L, Wang Y, Cui X, Li Y, Wang Y Database (Oxford). 2021; 2021.

PMID: 34642750 PMC: 8516408. DOI: 10.1093/database/baab065.

Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy.

Zhao L, Zhang Y, Liu F, Yang H, Zhong Y, Wang Y J Endocrinol Invest. 2021; 44(12):2709-2723.

PMID: 34043214 PMC: 8572220. DOI: 10.1007/s40618-021-01596-3.

References

Pieper R, Gatlin C, McGrath A, Makusky A, Mondal M, Seonarain M . Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics. 2004; 4(4):1159-74. DOI: 10.1002/pmic.200300661. View

Pisitkun T, Shen R, Knepper M . Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004; 101(36):13368-73. PMC: 516573. DOI: 10.1073/pnas.0403453101. View

Pisitkun T, Johnstone R, Knepper M . Discovery of urinary biomarkers. Mol Cell Proteomics. 2006; 5(10):1760-71. DOI: 10.1074/mcp.R600004-MCP200. View

Rifai N, Gillette M, Carr S . Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24(8):971-83. DOI: 10.1038/nbt1235. View

Adachi J, Kumar C, Zhang Y, Olsen J, Mann M . The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006; 7(9):R80. PMC: 1794545. DOI: 10.1186/gb-2006-7-9-R80. View

Soiland H, Soreide K, Janssen E, Korner H, Baak J, Soreide J . Emerging concepts of apolipoprotein D with possible implications for breast cancer. Cell Oncol. 2007; 29(3):195-209. PMC: 4618004. DOI: 10.1155/2007/487235. View

Ho J, Cheung S, Poon W, Lee Y, Ng I, Fan S . Down-regulation of retinol binding protein 5 is associated with aggressive tumor features in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2007; 133(12):929-36. DOI: 10.1007/s00432-007-0230-0. View

Zhang B, Chambers M, Tabb D . Proteomic parsimony through bipartite graph analysis improves accuracy and transparency. J Proteome Res. 2007; 6(9):3549-57. PMC: 2810678. DOI: 10.1021/pr070230d. View

Zimmerli L, Schiffer E, Zurbig P, Good D, Kellmann M, Mouls L . Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics. 2007; 7(2):290-8. DOI: 10.1074/mcp.M700394-MCP200. View

10.

Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands J . Urine in clinical proteomics. Mol Cell Proteomics. 2008; 7(10):1850-62. DOI: 10.1074/mcp.R800001-MCP200. View

11.

Hassan M, Waheed A, Yadav S, Singh T, Ahmad F . Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Cell Mol Life Sci. 2008; 66(3):447-59. PMC: 11131491. DOI: 10.1007/s00018-008-8463-x. View

12.

Cox J, Mann M . MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008; 26(12):1367-72. DOI: 10.1038/nbt.1511. View

13.

Huang D, Sherman B, Lempicki R . Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2008; 37(1):1-13. PMC: 2615629. DOI: 10.1093/nar/gkn923. View

14.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

15.

Anderson N . The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2009; 56(2):177-85. DOI: 10.1373/clinchem.2009.126706. View

16.

Nagaraj N, Mann M . Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J Proteome Res. 2010; 10(2):637-45. DOI: 10.1021/pr100835s. View

17.

Kentsis A, Monigatti F, Dorff K, Campagne F, Bachur R, Steen H . Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin Appl. 2010; 3(9):1052-1061. PMC: 2994589. DOI: 10.1002/prca.200900008. View

18.

Ryan D, Robards K, Prenzler P, Kendall M . Recent and potential developments in the analysis of urine: a review. Anal Chim Acta. 2010; 684(1-2):8-20. DOI: 10.1016/j.aca.2010.10.035. View

19.

Michalski A, Cox J, Mann M . More than 100,000 detectable peptide species elute in single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS/MS. J Proteome Res. 2011; 10(4):1785-93. DOI: 10.1021/pr101060v. View

20.

Wang R, Wang Z, Yang J, Pan X, De W, Chen L . MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011; 30(23):2644-58. DOI: 10.1038/onc.2010.642. View